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The association of the lymphotropic Epstein-Barr virus (EBV)' with certain human 
lymphoproliferative diseases and  its ability to  transform  normal lymphocytes into 
established in  vitro lines have prompted  the present  investigations. Primary EBV 
infection of certain age groups causes infectious mononucleosis, a self-limiting  lympho- 
proliferative disease (1). Furthermore, the regular association of EBV with Burkitt's 
lymphoma cells in vivo has led to serious consideration of this virus, possibly some 
special subtype, as the  etiological agent  of the  disease, alone or together with  co- 
factors (2). 
Three  lymphotropic herpesviruses are known  to cause neoplastic disease in ani- 
mals:  Marek's  disease herpesvirus  (MDHV)  in  chickens,  and  herpesvirus Saimiri 
(HVS)  and  herpesvirus Ateles  (HVA)  in  certain  new-world  monkeys.  Like  EBV, 
the proliferative interaction between  the genomes of these  herpesviruses and  their 
lymphoid target cells is dependent on a nonpermissive relationship (3-5). It is a so far 
unchallenged rule for all known  herpesviruses that  the  synthesis of viral proteins, 
including early products made before viral DNA synthesis, leads to an irreversible 
damage and eventually death of the host cell. MDHV  and HVS can induce a  lytic 
cycle in epithelial cells and fibroblasts, and their proliferation-inducing  effect is limited 
to  lymphoid cells. For EBV, the  site of the lyric viral replication is not yet known, 
whereas the nonpermissive, proliferative interaction with the lymphoid cells has been 
clearly demonstrated. It is important to define the human lymphoid cells that are the 
target for the proliferation-inducing effect of EBV in vitro and in vivo. 
In the mouse and  in man  the lymphoid system is divided into  two major com- 
partments,  thymus  dependent  (T)  and  bone  marrow  dependent  (B),  respectively. 
Surface markers and purification procedures now exist that  allow the isolation and 
* These investigations were conducted under contract no. N01 CP 3316 within the Special 
Virus Cancer Program of the National Cancer Institute, National Institutes of Health, U.S. 
Public Health Service, the Swedish Cancer Society, and the Damon Runyon Memorial Fund. 
1Abbrevialions used in this paper: BSS, balanced salt solution; E, sheep erythrocytes; EA, 
SRBC sensitized with 7S rabbit antibodies; EAC, SRBC sensitized with 19S rabbit antibodies 
and mouse complement; EBNA, Epstein-Barr virus-associated nuclear antigen; EBV, Epstein- 
Barr virus; F-Abwao, fluorescein isothiocyanate-conjugated MA-positive IgG; HVS, herpes- 
virus Saimiri;  MA, EBV-induced  membrane  antigen; MDVH, Marek's disease herpesvirus; 
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classification of these subpopulations in the human  system (6-8). The most reliable 
marker for peripheral B  lymphocytes seems to be the presence of easily detectable 
surface-bound immunoglobulin molecules that  are believed to function as antigen- 
specific receptors.  EBV-carrying  in  vitro  lines  are  known  to  have  surface-bound 
immunoglobulin (9)  and  it is therefore probable that  they have  originated from  B 
lymphocytes. The issue has been somewhat confused, however, by the recent finding 
of surface-bound immunoglobulin on T  lymphocytes by some investigators (10-12) 
although  in much  smaller quantities and  possibly with  another  localization in  the 
cell membrane. If this is correct, EBV transformation of T  lymphocytes might con- 
ceivably induce  some  steric  change  that  could  make  these  molecules more  easily 
detectable. This might lead to a  misinterpretation of the actual origin of the trans- 
formed cells. 
On  the  basis  of  these  considerations, it  seemed  logical to  combine  an  effort  to 
classify EBV-carrying in  vitro  lines with  regard  to  B-  and  T-  cell markers,  with 
studies of the presence of virus receptors on normal peripheral B and T  lymphocytes. 
Since  EBV-induced  lymphocyte  transformation  can  be  only  neutralized  by  anti- 
bodies against the viral envelope,  2 the target lymphocyte must carry specific receptors 
that  combine  with  some  envelope  component(s).  Such  receptors  can  be  demon- 
strated on the cell surface is most established, EBV-carrying nonproducer lines (13). 
We  have  previously studied  virus  adsorption  to  the  cell surface  in  such  lines by 
staining the  viral envelope antigens with  fluorescein-conjugated antibody immedi- 
ately after infection. We tried to apply the same method to peripheral lymphocytes 
but found  that  they adsorbed much  less virus than  the established cell lines. The 
fluorescence readings became less clear and it was difficult to estimate the number of 
the  receptor-positive cells.  In  the  present  study,  we  have  therefore  reversed  the 
system. Virus receptor-positive normal lymphocytes were specifically adsorbed to the 
surface of virus-producing cells in the P3HR-1  line. This approach was based on the 
following considerations: 
P3HR-1  is a high virus-producer clone, derived from the Jijoye line (14).  Approxi- 
mately 5% of the cells are in the productive cycle under ordinary culture conditions. 
These cells accumulate in rapid succession, early antigen, viral capsid antigen, and 
mature  virus particles  (15,  16).  In parallel, viral envelope antigens appear  in  the 
cell membrane in large quantities (17). They share antigenic specificity(ies) as MA, 
the EBV-induced membrane antigen (18,  19),  can can be demonstrated by staining 
live P3HR-1  cell suspensions with anti-MA-positive, fluorescein-conjugated human 
IgG (17).  Unlike most other EBV producer lines where cells tend to accumulate in 
the early phases of the viral cycle, with an excess of MA +  VCA -  cells (17), P3HR-1 
consists essentially of an MA  +  VCA  +  minority and an MA  -  VCA  -  majority, 
with little or no intermediate forms. 
Our approach was based on the consideration that  the viral envelope com- 
ponents  incorporated  into  the  membrane  of  the  virus-producing  cells  may 
attach to the viral receptors on the surface of receptor-bearing cells, including 
normal  lymphocytes.  This  was  found  to  be  the  case,  since  all  MA-positive 
cells and none of the MA-negative cells formed rosettes with normal lympho- 
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cyte suspensions. In this paper, we have studied the question whether B  or T 
lymphocytes are  responsible for  the  binding  and  whether rosette  formation 
could be specifically blocked by anti-MA-positive sera. 
Materials and Methods 
Preparation of E, EA, and EA C.--Sheep erythrocytes (E) were stored in Alsever's solution 
at 4°C. Before use they were washed three times in balanced salt solution ([BSS] pH 7.3) and 
adjusted to a 1% solution. 
SRBC sensitized with 7S rabbit antibodies (EA)  were prepared as follows: A rabbit anti- 
SRBC serum was fractionated on a Sephadex G-200 column into 19S and 7S fractions. Washed 
SRBC were shaken for 1 h at room temperature with the lowest dilution of 7S antibodies not 
giving hemagglutination and then incubated for another hour at 4°C.  The sensitized SRBC 
were washed three times in BSS before use. 
SRBC sensitized with 19S rabbit antibodies and mouse complement (EAC) were prepared 
as follows: Washed 5% SRBC were shaken for 1 h at room temperature with the lowest dilu- 
tion of 19S antibodies that failed to hemagglufinate and were then washed three times. An 
equal volume of 5% 19S-treated SRBC was then mixed with an equal volume of fresh A-strain 
mouse serum diluted 1:2. The serum was adsorbed with SRBC once before use. The cells were 
shaken horizontally at 37°C in a water bath for 15 min and washed three times. EAC incubated 
with heat-inactivated mouse serum for 30 min at 56°C served as the control. 
Tests for Surface Markers on Human Lymphoblastoid Lines.-- 
E binding:  i00 ~1 of a  1% SRBC solution was mixed with 100 #1 of a cell suspension con- 
taining 4  X  106 cells/ml. The cells were spun down in a small plastic tube. The pellet was 
incubated at 37°C for 15 min and then at 4°C for an additional hour, whereafter the cells were 
gently lifted onto a glass slide and examined under the microscope. 
EA binding: The lymphoblastoid cells and the indicator cells were spun down to a pellet 
as when testing for E-binding capacity. The pellet was then incubated at 37°C for 30 min and 
shaken apart. EA-binding ceils were counted in a Btirker chamber. 
EA C ~inding: Same as for EA. 
Surface  immunoglobulin:  A  commercially available polyvalent goat antihuman immuno- 
globulin serum was used in a direct immunofluorescent assay (Hyland 072-202; Hyland Div., 
Travenol Laboratories, Inc., Costa Mesa, Calif.). The conjugate was used in a dilution of 1:10. 
This dilution failed to stain a control cell line (MOLT-4, received from Dr. Minowada, Roswell 
Park Memorial Institute, Buffalo,  N.  Y.)  that was known to lack  surface immunoglobu]in 
(20). 5 X  105 cells in a small plastic tube were treated with 50 #1 of antiserum for 30 min at 
4°C. The cells were then washed three times in BSS and resuspended in 50/zl of a glycerol- 
BSS (1:1)  solution and immediately examined in the ultraviolet (UV) microscope. 
Purification  of Lymphocytes.--7-ml portions of freshly drawn heparinized whole blood were 
layered on 3-ml Ficoll-Isopaque gradients in 15-ml glass centrifuge tubes. The gradients were 
spun for 12  min at 680 g. The lymphocyte-monocyte layer at the upper interphase was re- 
moved and washed twice in BSS  and then further purified by the iron carbonyl technique. 
0.2 g of iron powder was mixed with a 10 ml cell suspension prepared in BSS and 10~ human 
AB-]- serum. The tube was incubated in a 37°C water bath for 30 min with shaking every 5 
min. The iron powder was removed by magnetism and the cells were washed three times. 
EB  Virus Receptor Assay.--lO 5 P3HR-1 cells were labeled with 50  #1 of a fluorescein-  or 
tetramethylrhodamine isothiocyanate-conjugated MA-positive IgG  (F-Abwao or  TRITC- 
Abwao, footnote 3)  for 30  min at 4°C  and washed twice in cold BSS.  The cells were then 
3 Lamon, E. V., I. Ernberg, and G. Klein. Detection of antigens determined by the Epstein- 
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resuspended in 50 #I of BSS containing 2  X  106 purified lymphocytes and incubated for 1 h 
at 4°C. Thereafter the cells were shaken gently and examined in the UV microscope for rosette 
formation. Cells that had more than two lymphocytes attached to their surface were scored as 
rosettes. 
Preparation of  Anti-lmmunoglobulin Column.--The  columns  were  prepared  as  earlier 
described by Wigzell et al. (7). Degalan beads (V26; Degussa Wolfgang AG, Hanau-am-Main, 
Germany)  were  incubated for  30  min  at  50°C  with  human  gamma  globulin  (Beriglobin; 
Behringwerke AG,  Marburg-Lahn, West Germany) at a  concentration of 5 mg/ml in BSS. 
The plastic beads were incubated overnight at 4°C  before being packed in the column and 
washed. A rabbit antihuman immunoglobulin serum diluted 1:2 was incubated in the column 
for 30 rain at room temperature and then washed away. The column was then ready for use. 
The efficiency of every column passage was checked by determining  the  percentage  of  Ig- 
positive cells in the passed population. Samples containing more than 2% contaminants were 
discarded. 
Blocking EXperiments.--Two groups of African patient sera were used. One was known to 
contain high antibody levels against the EBV-determined membrane antigen, as measured by 
the blocking of direct membrane fluorescence (21),  whereas the other had a  low or negative 
antibody level. 50 #1 of each serum was added to 10 ~ P3HR-1  cells,  pretreated with the F- 
Abwao conjugate and incubated for 30 min at 4°C to allow saturation of the viral determinants 
on the surface of the virus-producing cells.  After one wash in cold BSS the cells were mixed 
with 2 X  106 lymphocytes in 50 ~zl of BSS as described above. It was previously shown by two 
color fluorescence (22) that conjugates are too dilute to block all MA-reactive sites on the cell 
surface, whereas undiluted sera with high anti-MA level can block more or less completely. 
Maintenance of Lymphoblastoid Lines.--The  cell lines were propagated as stationary sus- 
pension cultures in Eagle's basal medium with 20% fetal calf serum. They were fed every 4th 
day and adjusted to an initial cell concentration of 2 X  105 cells/ml each time. 
Detection of EBV-Associated Nuclear Antigen, EBNA  Test.--Smears were prepared in the 
cytocentrifuge, or by spreading a concentrated suspension of washed ceils on clean slides and 
then air dried and fixed in chilled acetone. Human serum, which gave no reaction with Raji 
cells in the EBNA test (23) and which contained no detectable antibodies to EBV antigens by 
complement fixation or immunofluorescence, was used as a source of complement. All dilutions 
and washes were made in BSS. 
Mter fixation, the smears were dipped in BSS and treated with test serum (usually diluted 
1:8 and inactivated at 56°C for 30 min) containing complement (final dilution 1 : 10) at 37°C 
for 30 min in a  humid chamber. They were washed with stirring for 30 rain, stained with a 
suitable dilution of  FITC-conjugated  antihuman  ~lC/fllA  globulin  (Hyland  Laboratories, 
Los Angeles, Calif.)  at 37~C for 30 min or 4°C  for 90 rain, washed again, and mounted in 
BSS :glycerol 1:1. The slides were examined in a Leitz Ortholux microscope equipped with a 
vertical Ploem-type illuminator at oil immersion (54 X  or 100 X). 
RESULTS 
Surface Markers on Human Lymphoblastoid Lines.--Table I  shows the surface 
characteristics  of  the  human  lymphoblastoid  lines  tested.  All  EBV  genome- 
carrying  lines  had  surface-bound  immunoglobulin  and  none  of  these  lines 
could  bind  SRBC.  In  contrast,  the  T-cell-derived  line  MOLT-4  (20),  which 
does not carry the EBV genome according to the EBNA  test (23), did not have 
surface-bound  immunoglobulin  but  could  bind  SRBC.  11  of  the  17  EBV- 
carrying  lines  had  receptors  for  7S  Fc,  ranging  from  1  to  61%  of  the  cells. 
All lines had receptors for C'3 ranging from 2  to  100%. 
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TABLE  I 






characteristics  B-lymphocyte characteristics 
Capacity to  EA-binding*  EAC-  Surface-bound  binding*  bind SRBC  cells  cells  immunoglobulin 
%  % 
Daudi  BL:~  FOS  NEG  61  100  POS 
Raji  BL  ....  1  100  " 
Seraphine  BL  ....  1  98  " 
Namalwa  BL  ....  12  23  " 
Akuba  BL  ....  57  7  " 
Maku  BL  ....  0  100  " 
Sulubu  BL  ....  0  6  " 
Muniungi  BL  ....  29  58  " 
Rael  BL  "  "  0  2  " 
LY-46  BL  "  "  48  62  " 
NC-37  N  ....  30  100  " 
CB-B-1  CB  "  3  98  " 
CB-B-3  CB  ....  14  91  " 
CB-B-9  CB  ....  0  33  " 
L4-28  NPC  "  "  0  100  " 
SKL-1  L  ....  40  48  " 
JHTC-33  IM  ....  0  19  " 
MOLT-4§  ALL  NEG  POS  0  63  NEG 
For the origin of the lines, see ref. 13 and 20. 
* EA and NAC were tested with rat RBC covered with Fc and C'3 as described in Materials 
and Methods. 
~. BL,  Burkitt's lymphoma-derived lines.  N,  lines derived from  normal lymphocytes  of 
EBV-positive  donor.  NPC,  nasopharyngeal  carcinoma-derived  lymphoblastoid  line.  IM, 
infectious mononucleosis-derived line. ALL,  line established from acute lymphatic leukemia. 
CB,  cord blood lymphocytes transformed with EBV  (received from Doctors Jos~ M~n~zes 
and Wolfgang Leibold). L, leukemia-derived line. 
§ In the MOLT-4 line about 50~o of the cells formed rosettes with SRBC with  the tech- 
nique described. 
teristics  shown  in  Table  II  are  defined  in  analogy  with  the  human  system. 
Experiments  with  peripheral  lymphocytes  from  squirrel  monkeys  had  earlier 
shown that there was no over-lapping between the two populations of lympho- 
cytes  that  bind  SRBC  and  carry  surface  immunoglobulin.  All  three  EBV- 
transformed  lines  tested  lacked  receptors  for  SRBC.  They  seemed  to  carry 
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contrast,  the  herpesvirus  Saimiri  (HVS)-carrying  lines  did  bind  SRBC  and 
were  clearly  negative  for  surface  immunoglobulin.  The  EBV-transformed 
marmoset  line B-95-8 had receptors for C'3 that were not present on the other 
lines. No  7S  Fc receptors were found on any of the simian lines tested. 
EBV  Receptors  on Human  Peripheral  Lymphocytes.--Table  III  shows  that 
all  MA-positive  P3HR-1  cells,  labeled  with  the  F-Abwao  conjugate,  were 
capable  of  binding  lymphocytes  to  their  surfaces.  Virtually  no  MA-negative 
TABLE  II 
Surface Characteristics of Monkey Lymphoblastoid Lines 
Line  Viral  genome 
T-lymphocyte 
characteristics  B-lymphocyte  characteristics 
Capacity to  EA-bindiug EAC-binding  Surface-bound 
bind SRBC  cells  cells  immunoglobulin 
%  % 
KCSM-80*  SMUt  EBV  NEG  0  2  POS- +? 
KCSM-81*  SM*  EBV  NEG  0  3  POS- -4-? 
B-95-8§  MM~  EBV  NEG  0  86  POS- -4-? 
1670"  MM:~  HVSI]  POS  0  0  NEG 
MLC¶  MM:~  HVS[I  POS  0  0  NEG 
70-BM-2*  HVSII  POS  2  0  NEG 
* Received from Doctors Larry Falk and Friedrich Deinhardt. 
MM,  line derived from marmoset monkeys; SM,  line derived from squirrel monkeys. 
60-80%  of  HVS-transformed cells formed  SRBC  rosettes.  Surface-bound  immunoglobulin 
was stained with the same conjugate as for the human lines. The surface Ig staining of the 
three EBV-carrying lines was very weakly positive, with distinctly stained spots on most cells. 
§ Received from Dr. George Miller. 
II Herpesvirus Saimiri. 
¶  Received from Dr. Alan Rabson. 
TABLE  III 
Binding of Human Peripheral Lymphocytes to Virus-Producing Cells in the 
P3HR-1 Line 
MA-positive cells  MA-negative  cells  Rosette-forming cells*  forming rosettes$  forming rosettes§ 
%  %  % 
Exp. I  4.2  98  0.1 
Exp. II  2.3  93  0 
Exp. III  3.6  95  0 
* Binding was performed as described in Materials and Methods. 1,000 P3HR-1 cells were 
screened in a Btirker chamber and the percentage was calculated. 
100 MA-positive P3HR-1 cells were screened in the UV microscope and the percentage 
was calculated. 
§ 1,000 MA-negative P3HR-1 cells were screened in the UV microscope and the percentage 
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cell had the capacity to form rosettes (Figs.  1-4). The percentage of rosette- 
forming cells varied from 2.3 to 4.2 in three repeat experiments. 
Table IV shows that the number of rosette-forming cells was essentially the 
same, no matter whether P3HR-1 cells were pretreated with the MA-reactive 
conjugate or not. This rules out the possibility that binding was due to 7S Fc 
receptors on the lymphocytes. 
Table V  shows  that  the  binding  of lymphocytes to  MA-positive P3HR-1 
cells  could  be  partially  blocked  by  sera  with  high  antibody  titers  against 
EBV antigens but not, or only to a more limited extent, by sera with low EBV 
antibody titers. 
Table  VI  shows  that  passage  of  lymphocytes through  a  column  that  re- 
tained  B  lymphocytes, also  retained  the  cells  that  could bind  to  virus-pro- 
ducing P3HR-1 cells almost completely (Figs. 5 and 6). 
DISCUSSION 
EBV is only known to infect human and some nonhuman primate cells of 
lymphoid origin.  Since  the  virus  can  convert resting  lymphoid cells with  a 
limited life-span  into  permanent  in  vitro  lines  and  can  induce  benign  and 
perhaps even malignant lymphoproliferative disease in vivo, it is important to 
define the type of lymphocyte that is  susceptible to  the virus. We have at- 
tempted this in two different ways. Our first approach was to test established, 
EBV-carrying lines for three receptors normally associated  with  B  lympho- 
cytes, surface immunoglobulins,  7S Fc receptors, and C'3 receptors. We have 
also tested the lines for the capacity to form rosettes with SRBC, associated 
with  normal  T  lymphocytes.  A  human  lymphoblastoid  line  that  lacks  the 
EBV genome, MOLT-4 (20), was used for comparison. In addition, a number of 
simian  lymphoblastoid  lines,  converted by  EBV  or  by herpesvirus  Saimiri 
(HVS), respectively, were also tested in the same way. 
All EBV-carrying human lines tested had surface-associated immunoglobu- 
lin. The majority also carried receptors for CP3 and/or 7S Fc,  although they 
expressed them in different degrees. This is in line with the earlier findings of 
Nishioka (24), although the distribution of the receptors were slightly different 
in our experiments. These discrepancies may be due to the difference in  com- 
plement  sources and  in  the  techniques  involved in  rosette formation.  Since 
none  of the  EBV-carrying lines  could bind  SRBC,  all  this  evidence  points 
towards a B-lymphocyte origin, although it cannot be regarded as  conclusive. 
It must be remembered that the markers used have been defined with  regard 
to peripheral B  and T  lymphocytes. These are relatively small and  inactive, 
compared with the lymphoblastoid lines.  Since T-cell blasts induced in a  one- 
way mixed leukocyte culture or by concanavalin A  stimulation  retain  their 
capacity to bind SRBC, however, this marker might be expected to appear  on 
in vitro lines as well, provided they are T cell derived (Jondal, M., unpublished 
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TABLE IV 
Binding of Human Peripheral  Lymphocytes  to Virus-Producing  Cells in the 
P3HR-I Line in the Presence and Absence of the MA-Reactive Abwao Conjugate 
1373 
Rosette-forming cells 
MA-stained  P3HR-I cells  Unstained  P3HR-1 cells 
%  % 
Exp. I  4.2  4.5 
Exp. II  2.3  2.6 
Exp. III  3.6  3.5 
Binding assay was performed as described in Materials and Methods. 1,000 P3HR-1 cells 
were screened for rosette formation in a Biirker chamber and the percentage was calculated. 
negative  MOLT-4  that  did  not  carry  surface-bound immunoglobulin. This 
confirms the original suggestion that this line has been derived from T  cells (20). 
Our second approach was to look for EBV receptors on the surface of periph- 
eral lymphocytes. Adsorption of the virus is obviously a prerequisite for virally 
induced transformation, and while  the  presence  of  viral  receptors  does  not 
prove sensitivity to  the virus, absence of such receptors minimizes the prob- 
ability that  a  category  of  cells will be  susceptible to  viral infection and/or 
transformation.  It has been shown that EBV-induced transformation of cord 
blood lymphocytes is due to the attachment of enveloped virus.  2 
An attempt to assess EBV adsorption to lymphocyte surfaces by immediate 
membrane fluorescence (13)  was unsuccessful. Presumably, receptors  on  ma- 
ture  lymphocytes  are  relatively scarce,  or  the  number of  receptor-positive 
lymphocytes is  not  high  enough.  This  difficulty could  be  circumvented by 
using the virus-producing P3HR-1  line as the source of viral envelopes with 
the  appropriate  combining specificity for  virus  receptors  on  the  surface  of 
FIC.  1.  Virus-producing P3HR-1  cell, prelabeled with TRITC-conjugated  Abwao (MA- 
reactive reference reagent). The cell is surrounded with adherent lymphocytes. Phase contrast. 
X 3720. 
FIG. 2. Same field and magnification as in Fig. 1, photographs for TRITC fluorescence,  with 
546 nm green excitation light, 4 mm BG38 +  2 mm BG36 +  AL546 as primary filters, 580 nm 
interference plate and K590 barrier filter. X 3720. 
FIO. 3. Low-power view of a  virus-producing P3HR-1  cell, prelabeled with  the FITC- 
conjugated Abwao reference immunoglobulin, surrounded by adherent lymphocytes. X 2025. 
FIG. 4. Same field as in Fig. 3, photographs for FITC fluorescence.  470 nm blue excitation 
light, with 4 mm BG38 +  1.5 mm BG12 +  AL470 as primary filters, 495 nm interference 
plate and K510 barrier filter. X 2025. Note that none of the free P3HR-1  cells, not covered 
with adherent lymphocytes in Fig. 3, show any MA staining. 
FIG. 5. Low-power view, combined with contrast  and TRITC fluorescence, of TR_ITC- 
Abwao-labeled P3HR-1 cells, admixed to column-purified T lymphocytes. Note the absence 
of rosettes. X 936. 
FIG. 6. Same field as in Fig. 5, photographs for red emission, as in Fig. 2. X 936. Note that 
the MA-reactive cell is free of adherent lymphocytes. 1374  EBV  RECEPTORS  ON  HUMAN  B  LYMIPHOCYTES 
TABLE  V 
Specific Inhibition of Rosette Formation by Sera with High EBV Titers 
Sera with high EBV antibody titers  Inhibition of rosette formation 
around MA-positive  cells 
BI*  BT*  VCA titer$  Early antibody  tlter§  Exp. I  Exp. II 
%  % 
S.M.  1.00  8  80  < 10  26  18 
W.F.  0.98  16  320-640  >320  88  76 
G.K.  0.97  16  1,280  80  58  28 
K.K.  0.96  n.t.  160  n.t.  78  88 
M.M.  0.94  n.t.  640  2560  84  76 
D.L.  0.88  n.t.  1,280  n.t.  62  58 
O.J.  0.85  64  320-640  80  72  64 
E.J.  0.85  4  320  n.t.  70  56 
Sara with low EBV antibody titers 
Mean 67.3  Mean 58.0 
M.K.  0.16  <1  160  10  12  20 
A.K.  0.18  <1  20  <10  2  8 
P.H.  0.03  < 1  20  10  6  2 
N.M.  0.03  <1  <10  0  2 
R.T.  0.05  <1  <10  <10  18  22 
S.O.  0.06  < 1  10  < 10  22  16 
R.K.  0.02  < 1  10-20  < 10  8  6 
Mean 9.7  Mean 10.9 
Two representative experiments are shown in the table.  100 MA-positive P3HR-1 cells 
were screened in the UV microscope for rosette formation. 
* Direct membrane fluorescence-blocking  assay for EBV-determined membrane antigens 
(MA) was performed as previously described.  ~ Blocking Index (BI)  is defined as the capacity 
of the serum to inhibit staining of a fluorescein-conjugated reference serum (Mutua)  by first 
treating the cells with the test serum and then with the reference serum (1:8) after washing. ~ 
Blocking Titer (BT)  is defined as the concentration of test serum giving a 50% reduction of 
positive cells labeled by the reference conjugate. 
:~ Antibody titer against EBV-determined viral capsid antigen (15). 
§ Antibody titer against EBV-determined early antigen (16). 
other  cells.  It  has  been  shown  previously  that  the  virus  cycle proceeds  rela- 
tively rapidly to  completion in the P3HR-1  line and that  cells containing late 
viral envelope material with MA specificity  in  their  plasma  membranes  (17). 
By prestaining  the plasma  membrane  with MA-positive conjugates  these cells 
could be easily identified. Almost all MA-positive P3HR-1 cells formed rosettes 
with unfractionated  lymphocytes,  whereas  none  of the  MA-negative cells did 
so.  It  might  be  objected,  however,  that  the  lymphocytes  attached  to  the 
MA-stained  P3HR-1  cells  by  their  7S  Fc  receptors,  rather  than  via  EBV MIKAEL JONDAL AND  GEORGE KLEIN  1375 
TABLE VI 
Binding  of Column-Purified Human  T Lymphocytes to Virus-Producing 
Cells in the P3HR-1 Line 
M-A-positive  cells  forming rosettes 
Unfractionated cells  Fractionated cells 
Exp. I  98  5 
Exp. II  93  7 
Exp. III  95  8 
100 MA-positive P3HR-1 cells were screened in the UV microscope  and the percentage of 
rosette-forming  cells  was calculated. For details of column passage see Materials and Methods. 
EM, 4001, p 2. 
receptors.  When  the  experiments  were  repeated  with  unstained  P3HR-1 
cells, the proportion of rosette-forming cells was the same, however, as in the 
prestained population. Therefore, it could be concluded that the binding was 
not mediated through the 7S Fc receptors. The second alternative that lympho- 
cytes  attached  by  EBV  receptors  was  confirmed  by  blocking  experiments. 
Sera  containing  high antibody fiters against the EBV-determined MA could 
inhibit rosette formation to a  considerable extent, whereas sera with insignifi- 
cant or low MA titers failed to do so. The fact that this blocking was partial 
rather than complete is either due to a  large excess of viral envelope material 
on the surface of virus-producing cells, and/or to a steric difference between the 
anti-MA  antibody-binding  sites  and  the  sites  combining  with  the  virus  re- 
ceptors on the lymphocyte surface. 
The  finding  that  unfractionated  lymphocyte populations  formed  rosettes 
regularly with  100%  of the MA-positive P3HR-1  cells whereas lymphocytes 
passed through an anti-immunoglobulin column were unable to make rosettes 
must be interpreted  to mean  that  only B  lymphocytes had  EBV receptors. 
A more direct way to prove this would be to stain the adherent lymphocytes 
in the rosettes with a fluorescein-conjugated anti-immunoglobulin serum. This 
was  attempted  with  a  double-staining  procedure,  but  most  of  the  rosettes 
disintegrated  during  these  manipulations.  The  few  incomplete  rosettes  left 
consisted entirely of immunoglobulin-positive lymphocytes. This would further 
support the view that the relevant function of the column in the present ex- 
periments  was  the  removal  of  immunoglobulin-posifive  lymphocytes.  Care 
should otherwise be taken in interpreting the effect of such a  column passage 
as the column consists of immune complexes and secondarily removes cells with 
7S  Fc receptors.  Current  knowledge  suggests,  however,  that  these  receptors 
are also localized on B  lymphocytes with the exception of educated T  lympho- 
cytes in the mouse system (25,  26). 
The results obtained in this study thus suggest that EBV acts on the bone 
marrow-derived  lymphocyte  system  in  man.  It  remains  an  open  question, 1376  EBV  RECEPTORS  ON  HUMAN  B  LYMPHOCYTES 
however, whether all B lymphocytes or only a minority are susceptible to the 
virus. 
SUMMARY 
Human  peripheral  lymphocytes  were  investigated  for  receptors  binding 
Epstein-Barr virus (EBV) because of the regular association of this virus with 
infectious mononucleosis and Burkitt's lymphoma. 
This  was  done  by a  cytoadherence technique  where  virus-producing cells, 
displaying  fresh  viral  determinants  in  their  cytoplasmatic  membrane,  were 
mixed with  lymphocytes. Unfractionated lymphocytes were  found to  adhere 
to these cells in contrast to column-purified T  lymphocytes. The specificity of 
the binding was confirmed by blocking experiments that showed that sera con- 
taining  high  titers  of  antibodies  directed  against  the  virus  could  partially 
inhibit  the  adherence  in  contrast  to  low-titer  sera.  It  is  concluded  that  B 
lymphocytes, in contrast to T  lymphocytes, have receptors for EBV. 
In a second line of experiments it was found that established human lympho- 
blastoid lines  that carry the EBV genome had receptors characteristic for B 
lymphocytes and did not form T-lymphocyte rosettes.  In contrast,  a  line of 
known T-lymphocyte origin that did not carry the EBV genome had receptors 
characteristic for T  lymphocytes. 
EBV-transformed  simian  lymphoblastoid  lines  had  surface  markers  indi- 
cating a B-lymphocyte origin in contrast to HVS-transformed simian lines that 
lacked surface immunoglobulin but carried receptors for sheep red blood cells. 
We are grateful to Doctors Jos~ M~n~zes and Wolfgang  Leibold for the cord blood-derived 
cell lines, Doctors  Larry Falk and Friedrich Deinhardt for the HVS-carrying  simian lines, and 
to Miss Anita Westman for valuable technical assistance. 
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